Conclusion At its simplest this case represents two disease processes occurring by chance in the same patient. However both conditions are uncommon.

A second possibility is that there is a common genetic link. The patient's father had a history of idiopathic thrombocytopenia. Some cases of evolution from ITP to SLE have been reported. It seems possible therefore that there may be a genetic component to his predisposition to lupus. Linkage studies of SLE using microsatellites have revealed a wide range of genome susceptibility loci. Although haemochromatosis is the most commonly inherited single gene disorder, there was no known family history here.

A further possibility was that the two conditions had an additive effect. A high ferritin can reflect lupus activity. It also acts a source of iron causing production of hydroxyl radicals from oxygen and extensive tissue damage.

In conclusion there are several possible theories causing multi-organ failure in this case.

REFERENCE

- Matsumoto T, Yoshimine MD, Shimouchi K, *et al.* The liver in systemic lupus erythematosus: Pathologic analysis of 52 cases and review of Japanese autopsy registry data. *Hum Pathol.* 1992;23(10):1151-8

AB0074 PULSE METHYLPREDNISOLONE AND CYCLOPHOSPHAMIDE THERAPY IN THREE SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH BRONCHIOLITIS OBLITERANS ORGANISING PNEUMONIA AS THE INITIAL MANIFESTATION

JC Tseng, HH Cheng, RJ Hu, LY Lu. *Allergy, Immunology and Rheumatology, Veterans General Hospital, Kaohsiung, Taiwan, R.O.C*

10.1136/annrheumdis-2001.119

Background Diverse pleuropulmonary manifestations are common in patients with systemic lupus erythematosus (SLE). Bronchiolitis obliterans organising pneumonia (BOOP) is a pathologic entity characterised by the formation of fibrous tissue plugs within terminal bronchioles and alveolar ducts. Although BOOP has been associated with several connective tissue disorders, there are rare reports of BOOP in patients of SLE as the initial manifestation.

Objectives We described three SLE patients with open lung biopsy-proved BOOP as the initial manifestation which responded well to pulse intravenous methylprednisolone and cyclophosphamide therapy. All three cases presented with fever, cough and dyspnea. Chest radiographs and CT scan of lung revealed bilateral pulmonary infiltrates. BOOP was confirmed by open lung biopsy. Pulmonary vasculitis was also demonstrated in lung histopathology in one case.

Methods

Results The pulmonary lesions and respiratory illnesses responded well to monthly pulse intravenous methylprednisolone and cyclophosphamide therapy.

Abstract AB0074 Table 1

	Case 1	Case 2	Case 3
Sex	Female	Male	Male
Age	43	56	47
ANA	1:160, speckled	1:320, homogeneous	1:320, homogeneous
anti-ENA	SS-A, SS-B	Negative	Negative

anti-dsDNA	Negative	69 IU/ml	>400 IU/ml
Clinical and laboratory data.			

Conclusion

AB0075 AORTITIS SYNDROME (TAKAYASU'S ARTERITIS) ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS

C Korkmaz. *Rheumatology, Osmangazi University, Eskisehir, Turkey*

10.1136/annrheumdis-2001.120

Background Aortitis syndrome (Takayasu's arteritis) associated with various autoimmune diseases have been reported.

Objectives We report the rare association of aortitis syndrome with SLE in two patients.

Methods Case report.

Results Case 1. A 49-year-old woman admitted with Raynaud's phenomenon, right upper extremity claudication, malar rash, and oral ulcerations. Examination showed that her right radial pulse was not palpable. A systolic bruit was heard over her right carotid artery. Laboratory results were as follows: erythrocyte sedimentation rate 89 mm/h, leukopenia, thrombocytopenia, positive ANA, positive anti-ds-DNA. An aortogram demonstrated a complete obstruction of the right subclavian artery near its origin. The patient was diagnosed as having SLE and TA based on ACR criteria for both diseases. She was treated with prednisolone and azathioprine. 6 months later, her right radial pulse was weakly present.

Case 2. A 30-year-old man was diagnosed in 1985 as having SLE based on malar rash, arthritis, positive ANA, positive anti-ds-DNA, hematologic abnormalities. He was treated with prednisolone (P) and azathioprine. He was readmitted in 1992 with progressive difficulty walking and symptoms of lower extremity claudication. Aortogram revealed occlusion of the abdominal aorta below the renal arteries. In 1994, he developed renal and cerebral involvement and superior vena cava syndrome (SVCS). He was again treated with P and cyclophosphamide (C). In 2000, A computed tomogram of the thorax confirmed SVCS due to mediastinal fibrosis. He has been using P and tamoxifen for 1 month.

Conclusion Our experience with these cases suggests that all patients with SLE be followed carefully for the development of occlusive arterial involvement.

AB0076 WARTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

C Korkmaz, S Ürer, I Zubaroglu. *Rheumatology, Osmangazi University, Eskisehir, Turkey*

10.1136/annrheumdis-2001.121

Background It is widely accepted that patients with systemic lupus erythematosus (SLE) have an increased susceptibility to infections, and infections have also been considered to be important in triggering SLE. An increased frequency of bacterial and mycotic infections have been reported. SLE is also associated with few viral infections.

Objectives During their follow-up many patients with SLE were found to have viral warts. We therefore undertook this study to determine the prevalence of warts in patients with SLE.

Methods Definite SLE and rheumatoid arthritis (RA) were diagnosed on the basis of criteria by the ACR. Study included 44 SLE patients (39 F, 5 M; age 36.4 years), 71 RA patients (59 F, 12 M; age 49 years). The prevalence of warts was also determined in healthy medical students and their neighbours.

Results Warts occurred significantly ($p < 0.012$, $p < 0.001$) more often in patients with SLE than in the RA patients and healthy control patients respectively. Table shows the prevalence of warts in patients with SLE and control patients.

Abstract AB0076 Table 1

	Warts (+)	Warts (-)	Total
SLE	16	28	44
RA	11	60	71
Healthy Control	14	91	105

Conclusion The findings suggest that some deficiency in the immune mechanisms of patients with SLE predisposes them to develop warts.

AB0077 CIPROFLOXACIN-RELATED ACUTE PERIPHERAL NEUROPATHY IN A PATIENT WITH SLE

J Singh, R Brasington. Department of Medicine, Division of Rheumatology, Washington University School of Medicine, St. Louis, USA

10.1136/annrheumdis-2001.122

Background Ciprofloxacin is a broad-spectrum antibiotic commonly used for skin, respiratory tract and urinary tract infections. It is associated with a very few serious adverse effects.^{1,2} In a report of worldwide experience with ciprofloxacin, peripheral neuropathy was reported in one patient only, with no details available.³ We describe the first case of ciprofloxacin-related peripheral neuropathy in a patient with SLE.

Objectives

Methods

Results The patient, 18-yr-old African-American female, presented with five-day history of an acute onset of progressive tingling, numbness and weakness of both lower extremities. The symptoms began one day after the initiation of ciprofloxacin for treatment of urinary tract infection. At the time of hospital admission, patient was found to have bilateral symmetrical decrease in pain, temperature and light touch perception below knees, with weakness of both plantar- and dorsi-flexion of the ankle and an absence of bilateral ankle reflexes. Nerve conduction studies and EMG were done, which revealed a predominant sensory axonal neuropathy in lower extremities, with relative sparing of the motor component. MRI of the spine didn't reveal any evidence of transverse myelitis. A diagnosis of ciprofloxacin-related peripheral neuropathy was made. Ciprofloxacin was

discontinued. During the two day stay in the hospital, she started regaining the sensation in both lower extremities, without any other intervention. Within 10 days of the discontinuation of ciprofloxacin, her symptoms had completely resolved. She had no recurrence of the symptoms and no residual neurological deficit.

Conclusion Peripheral neuropathy is an uncommon manifestation of SLE. It is more rarely seen as adverse effect of ciprofloxacin. It is possible that the presence of SLE, and the concomitant use of hydroxychloroquine in our patient may have predisposed her to the occurrence of this rare adverse effect of ciprofloxacin. A similar case of possible drug interaction has been reported in a patient receiving therapy with ciprofloxacin, NSAIDs and chloroquine, who experienced neurological adverse effect.⁴

REFERENCES

- 1 Rahm V, Schacht P. Safety of ciprofloxacin. A review. *Scand J Infect Dis Suppl.* 1989;**60**:120-8
- 2 Schacht P, Arceri G, Hullmann R. Safety of oral ciprofloxacin. An update based on clinical trial results. *Am J Med.* 1989;**87**(5A):985-1025
- 3 Reiter C, Pfeiffer M, Hullman RN. Safety of ciprofloxacin based on Phase IV studies in the Federal Republic of Germany. *Am J Med.* 1989;**87**(5A):1035-1085
- 4 Roloff J, Vinge E. Neurologic adverse effects during concomitant therapy with ciprofloxacin, NSAIDs and chloroquine: possible drug interaction. *Ann Pharmacother.* 1993;**27**(9):1058-9

AB0078 PULSE METHYLPREDNISOLONE AND CYCLOPHOSPHAMIDE THERAPY IN THREE SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH BRONCHIOLITIS OBLITERANS ORGANISING PNEUMONIA AS THE INITIAL MANIFESTATION

JC Tseng, HH Cheng, RJ Hu, LY Lu. Allergy, Immunology and Rheumatology, Veterans General Hospital, Kaohsiung, Taiwan, R.O.C

10.1136/annrheumdis-2001.123

Background Diverse pleuropulmonary manifestations are common in patients with systemic lupus erythematosus (SLE). Bronchiolitis obliterans organising pneumonia (BOOP) is a pathologic entity characterised by the formation of fibrous plugs within terminal bronchioles and alveolar ducts. Although BOOP has been associated with several connective tissue disorders, there are rare reports of BOOP in patients with SLE as the initial manifestation.

Objectives We describe three SLE patients with open lung biopsy-proved BOOP as the initial manifestation.

Methods All three cases presented with acute/subacute chest symptoms of fever, cough and dyspnea. Chest radiographs and CT scan of lung revealed bilateral pulmonary infiltrates. BOOP was confirmed by open lung biopsy. Pulmonary vasculitis was also demonstrated in lung histopathology in one case. The pulmonary lesions and respiratory illnesses responded to pulse intravenous methylprednisolone and cyclophosphamide therapy.

Results

Abstract AB0078 Table 1

	Sex	Age	ANA	anti-ENA	anti-dsDNA	Anticardiolipin antibody	Duration of pulse cyclophosphamide therapy
Case 1	Female	43	1:160, speckled	SS-A, SS-B	Negative	Positive	3 months
Case 2	Male	56	1:320, homogeneous	Negative	69 IU/ml	Positive	3 months
Case 3	Male	47	1:320, homogeneous	Negative	>400 IU/ml	Negative	2 months

Clinical and laboratory data.